IBRX Latest Press Releases

-- October 14, 2026 --

FDA Expands ANKTIVA Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease Business Wire 4:18 PM

-- October 8, 2026 --

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium Business Wire 8:30 AM

-- October 2, 2026 --

These High-Voltage Stocks Are Suddenly Impossible to Ignore Globe Newswire 11:44 AM

-- October 1, 2026 --

HLS Therapeutics Announces Board of Directors Changes PRNewswire 7:00 AM

-- September 14, 2026 --

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors Globe Newswire 10:30 AM

-- August 10, 2026 --

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman Business Wire 9:00 AM

-- August 4, 2026 --

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million Business Wire 7:30 AM

-- July 29, 2026 --

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer Business Wire 6:45 PM

-- June 8, 2026 --

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet Globe Newswire 9:01 AM

-- June 3, 2026 --

The Multi-Billion-Dollar Search for Better Glioblastoma Treatments Globe Newswire 9:28 AM

-- June 1, 2026 --

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 Business Wire 1:52 PM

-- May 26, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX Globe Newswire 4:00 PM

ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX Business Wire 1:27 PM

Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors Globe Newswire 9:05 AM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX PRNewswire 9:01 AM

IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 Business Wire 8:56 AM

IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman PRNewswire 4:52 AM

-- May 25, 2026 --

IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX Globe Newswire 7:22 PM

IBRX DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX Newsfile 4:53 PM

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS Globe Newswire 11:05 AM

-- May 24, 2026 --

IBRX DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX Newsfile 4:47 PM

-- May 23, 2026 --

IBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm PRNewswire 7:37 PM

IBRX IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX Newsfile 4:42 PM

-- May 22, 2026 --

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX Globe Newswire 6:11 PM

ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX Business Wire 5:25 PM

IBRX DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX Newsfile 4:37 PM

IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th Globe Newswire 4:05 PM

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations - Lowey Dannenberg, P.C. Globe Newswire 3:08 PM

Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP PRNewswire 1:09 PM

IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims - Hagens Berman Globe Newswire 12:48 PM

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS Business Wire 7:30 AM

ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation Business Wire 7:30 AM

TUESDAY INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Globe Newswire 6:05 AM

-- May 21, 2026 --

INVESTOR DEADLINE TUESDAY: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law PRNewswire 5:18 PM

IBRX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX Newsfile 4:33 PM

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX Globe Newswire 1:16 PM

DEADLINE ALERT for SMCI, IBRX, and PINS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders Globe Newswire 12:08 PM

IBRX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 PRNewswire 9:14 AM

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX) Newsfile 9:13 AM

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS PRNewswire 9:00 AM

-- May 20, 2026 --

IBRX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX Newsfile 4:33 PM

INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP Business Wire 10:48 AM

-- May 19, 2026 --

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 Business Wire 8:30 PM

IBRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX Newsfile 4:42 PM

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PRNewswire 3:47 PM

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC Newsfile 2:16 PM

CLASS ACTION REMINDER: Berger Montague Advises ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Inquire About a Securities Fraud Lawsuit by May 26, 2026 Globe Newswire 9:14 AM

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman Globe Newswire 9:06 AM

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 Business Wire 7:30 AM

-- May 18, 2026 --

IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th Globe Newswire 5:40 PM

ImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm PRNewswire 2:56 PM

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC Newsfile 1:01 PM

IMMUNITYBIO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX Globe Newswire 12:53 PM

Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc. Globe Newswire 12:35 PM

IBRX 8-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman PRNewswire 12:21 PM

ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 Business Wire 7:30 AM

-- May 16, 2026 --

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States Business Wire 1:35 PM

-- May 15, 2026 --

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX PRNewswire 10:00 PM

IBRX INVESTOR NOTICE: ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman Globe Newswire 11:10 AM

IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm Globe Newswire 9:00 AM

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes